NDAINTRAMUSCULARINJECTABLE
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUNELLE is a fixed-dose combination injectable contraceptive containing estradiol cypionate and medroxyprogesterone acetate, administered intramuscularly. It prevents pregnancy through hormonal suppression of ovulation and cervical mucus thickening. The product targets women seeking convenient monthly contraception without daily pill adherence.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), brand roles are focused on legacy maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LUNELLE offers exposure to contraceptive marketing, managed care negotiation, and patient retention strategies in a mature, LOE-stage product. Career growth is limited; roles focus on defending market share and transitioning to generic/authorized generic launch support rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on LUNELLE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.